NeuroOne Medical (NMTC) Q2 2026: 1RF Revenue Jumps 72% as Clinical Adoption Expands

2026-05-12 | By EarningsIQ Research

NeuroOne Medical delivered standout 1RF system growth, up 72% year over year, driven by expanding clinical adoption and procedure volume. The company maintained disciplined operating expenses, advanced multiple pipeline programs, and set the stage for international expansion pending ISO certification. Management reaffirmed full-year guidance, signaling confidence in continued product momentum and upcoming commercialization milestones.

Summary

• 1RF System Uptake Accelerates: Robust clinical demand and procedure stacking are driving rapid product adoption.
• Pipeline Progress Across Pain and Drug Delivery: Multiple new programs are advancing toward commercialization and clinical validation.
• International and Distribution Levers Unlocked: ISO progress and distributor partnerships set up new growth vectors for late 2026 and beyond.

Business Overview

NeuroOne Medical Technologies develops and commercializes minimally invasive neuromodulation and ablation devices for neurological disorders, including epilepsy and chronic pain. The company generates revenue primarily from sales of its 1RF brain and trigeminal nerve ablation systems, which are used by neurosurgeons to treat drug-resistant epilepsy and facial pain. NeuroOne’s business model focuses on product sales, strategic distribution partnerships (notably with Zimmer Biomet, medical device distributor), and pipeline expansion into drug delivery and pain management markets.

Performance Analysis

Product revenue surged 72% year over year, reaching $2.4 million, exclusively driven by increased 1RF system sales and procedure volume. The company saw broadening adoption, especially as neurosurgeons are able to “stack” facial pain procedures in a single day, improving utilization and throughput. Despite the absence of license revenue this quarter—compared to a prior year period that benefited from a Zimmer Biomet agreement—gross profit grew on higher product sales, with gross margin holding steady at 53.8%.

Operating expenses remained tightly managed, flat year over year at $3.4 million, reflecting stable R&D and SG&A spend. Net loss narrowed modestly despite the lack of high-margin license revenue, underscoring improving core business leverage. Cash and working capital declined sequentially, but the company exited the quarter with no debt and $2.8 million in cash, plus $2.4 million in receivables expected to convert in Q3.

• Clinical Utilization Efficiency: Facial pain cases are being scheduled in batches, increasing per-center procedure throughput and supporting faster adoption.
• Margin Stability Amid Mix Shift: Gross margin compression was limited despite the absence of license revenue, reflecting improving product economics.
• Disciplined Expense Control: R&D and SG&A were held flat, preserving runway as the company invests in new pipeline programs.

NeuroOne’s core business is now almost entirely product revenue-driven, with future upside tied to drug delivery and pain management programs as they move closer to commercialization and international rollout.

Executive Commentary

Strategic Positioning

1. 1RF Platform Clinical Momentum

Repeatable, reliable clinical outcomes are fueling adoption in both brain and facial pain procedures. The company highlighted all 16 trigeminal neuralgia cases resulted in patients being pain-free, a compelling clinical value proposition. The device’s single-placement design reduces patient discomfort and procedure time, differentiating it from traditional multi-probe systems.

2. Pipeline and Commercial Expansion

Drug delivery system commercialization remains on track for late fiscal 2026, with the company finalizing sterilization and packaging validation and moving to distributor-led sales for animal and investigational use. The company also advanced its vertebral nerve ablation and spinal cord stimulation programs, with preclinical and animal studies ongoing and product enhancements identified.

3. International Market Entry and Regulatory Progress

Completion of the Stage 2 ISO 13485 audit positions NeuroOne for international market entry in late 2026, leveraging Zimmer Biomet’s distribution reach for FDA-clearance-accepting geographies. The company is also evaluating additional distributor partnerships for territories outside Zimmer’s rights, expanding the addressable market.

4. Capital Structure and Leadership Stability

NeuroOne regained NASDAQ compliance following a reverse split, adding institutional investor confidence and executive bench strength with a new Chief Business Officer and a planned CFO transition to the current COO, ensuring continuity as the business scales.

Key Considerations

NeuroOne’s quarter was defined by operational execution, clinical validation, and strategic pipeline progress, positioning the company for multi-year growth across core and emerging segments.

Key Considerations:

• Clinical Data as a Growth Engine: Peer-reviewed publications and real-world case series are validating technology features and supporting physician adoption.
• Distribution-Driven Expansion: Partnerships with Zimmer Biomet and new distributors will be critical for scaling both domestically and internationally.
• Pipeline Timing and Commercialization: Drug delivery and spinal pain programs are progressing, but commercial impact is weighted toward late 2026 and beyond.
• Cash Conversion and Runway: Receivables conversion in Q3 provides near-term liquidity, but ongoing investment in pipeline and regulatory milestones will require continued financial discipline.

Risks

Execution risk remains around the timing and scale of new product launches, particularly for the drug delivery and pain management programs, where regulatory, distribution, and market access hurdles could delay revenue impact. Cash burn and working capital drawdown require monitoring, as the company’s ability to self-fund growth will depend on sustained product adoption and timely pipeline milestones. International expansion is contingent on ISO certification and successful distributor ramp-up, both of which are subject to external regulatory and operational factors.

Forward Outlook

For the third quarter, NeuroOne expects continued sequential growth in product revenue, driven by expanding procedure volume and new center onboarding.

• Drug delivery system commercialization remains targeted for late fiscal 2026, initially for investigational and animal studies.
• International market entry is expected in late 2026, pending ISO certification and regulatory clearance.

For full-year 2026, management reaffirmed product revenue guidance of $10.5 million, explicitly excluding contributions from drug delivery and facial pain segments. CEO Dave Rosa noted, “It still remains the same, the guidance. And you're correct. It doesn't include anything from those areas.”

• Guidance does not assume material revenue from pipeline or new geographies until late in the fiscal year.
• Ongoing clinical data generation and distribution partnerships are expected to drive upside in subsequent periods.

Takeaways

NeuroOne is executing on its core 1RF platform while methodically advancing a diversified neuromodulation pipeline, setting up multiple growth catalysts for 2026 and beyond.

• Clinical Validation Drives Adoption: Real-world outcomes and procedural efficiency are compelling neurosurgeons and supporting rapid procedure ramp.
• Pipeline and Distribution Leverage: Drug delivery and spinal pain programs, plus international expansion, provide optionality but are not yet in guidance, creating potential for upside surprises.
• Watch for Commercial Milestones: Key inflections will come from ISO certification, distributor contracts, and first-in-human pipeline data, which could accelerate growth or expose execution risk if delayed.

Conclusion

NeuroOne’s Q2 2026 results underscore strong execution in its core ablation platform, disciplined cost management, and advancing pipeline programs. As the company approaches key regulatory and commercial milestones, its ability to convert clinical validation into sustained revenue growth and international scale will be the primary driver of long-term value creation.

Industry Read-Through

NeuroOne’s results and commentary highlight the accelerating adoption of minimally invasive neuromodulation and ablation technologies in neurology and pain management. The company’s success in stacking procedures and leveraging single-use, multi-contact devices points to a broader industry shift toward procedural efficiency and patient comfort, which could pressure legacy multi-probe systems and open new markets for device innovators. Distribution partnerships and international regulatory pathways are increasingly critical for smaller medtechs to scale, while clinical data generation remains the linchpin for physician adoption and reimbursement. Competitors and investors across neurotechnology should monitor the pace of ISO certifications, distributor ramp, and pipeline-to-product conversion as leading indicators for sector growth and consolidation.

NMTC Healthcare Medical Devices Neuromodulation Product Launch Distribution Pipeline Clinical Data